Global Pharmaceuticals Company Receives FDA Approval For Parkinson's Disease Treatment

Amneal Pharmaceuticals, Inc. recently announced that the U.S. Food and Drug Administration (FDA) has approved CREXONT® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease (PD). This novel formulation promises to address some of the longstanding challenges faced by patients and healthcare providers in managing this progressive neurological disorder. $Amneal Pharmaceuticals (AMRX.US)$